- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Addition Technology’s corneal implants approved for use in Canada
Des Plaines, IL-Addition Technology has received regulatory clearance from Health Canada to market its corneal implants (Intacs) for keratoconus and myopia indications.
Des Plaines, IL-Addition Technology has received regulatory clearance from Health Canada to market its corneal implants (Intacs) for keratoconus and myopia indications.
“Over the past couple of years, there has been considerable interest in [the implants] in Canada,” said William M. Flynn, president and chief executive officer of Addition Technology. “We have trained quite a few surgeons to date and expect this procedure to be adopted fairly rapidly within the ophthalmic community.”
The implant will be distributed in Canada by I-MED Pharma, which also plans to begin distributing Addition Technology’s artificial cornea (AlphaCor) and an orbital implant in development (AlphaSphere) within the next year.
